查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611546

放射性皮肤炎市场规模、份额、趋势分析报告：依产品、通路、地区、细分市场预测，2025-2030

Radiodermatitis Market Size, Share & Trends Analysis Report By Product (Topical, Dressings), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

放射性皮肤炎市场成长和趋势

根据Grand View Research, Inc.的最新报告，到2030年，全球放射性皮肤炎市场规模预计将达到5.571亿美元，预计2025年至2030年该市场将以4.0%的复合年增长率增长。

全球癌症发生率上升是推动市场成长的关键因素。随着癌症发生率的增加，越来越多的患者接受放射治疗作为治疗计划的一部分。 2024 年2 月，世界卫生组织估计，大约20% 的人会在一生中的某个阶段被诊断出患有癌症，大约九分之一的男性和十二分之一的女性将受到癌症的影响，因此对癌症的需求不断增长。这种情况的特征是由于辐射暴露引起的皮肤发炎和损伤，需要专门的治疗，重点是缓解症状和促进癒合。因此，製药和医疗设备公司正在优先开发创新治疗方法和产品来解决放射性皮肤炎。

在癌症治疗期间提高对患者照护的认识和重视对于改善治疗结果起着重要作用。医疗保健提供者越来越意识到需要解决与放射治疗相关的副作用，例如放射性皮肤炎。 《生物工程与转化医学》2024 年 5 月的一篇评论强调了自 20 世纪 80 年代末期以来水凝胶在药物传输、化妆品和组织再生方面的临床应用。聚合物化学和製造领域的最新进展已经产生了 100 多种由天然、合成或复合材料製成的经 FDA 和 EMA核准的水凝胶产品。这些产品用于多种应用，包括组织再生、脸部矫正、伤口覆盖和药物输送，注射和非注射形式均用于临床测试。

放射性皮肤炎市场报告亮点

  • 到 2024 年，局部产品细分市场占据主导地位，市场占有率为 71.7%，这主要是由于易于获得、更加方便以及相对于口服替代品的优势。这些产品预计将显着增长，因为它们有多种剂型，包括乳膏、凝胶和软膏，可根据患者需求量身定制。
  • 在分销管道方面，由于药局数量的增加，零售药局细分市场将在2024年占据39.4%的较大份额。零售药局占医院处方的很大一部分。
  • 欧洲凭藉其先进的医疗基础设施、较高的护肤护理治疗意识以及大量接受放射治疗的患者，以34.0%的市场占有率主导全球市场。
  • 由于重大研发倡议创造了有希望的成长机会，北美占据了第二大市场占有率。该地区的先进治疗产品是促进放射性皮肤炎行业成长的关键因素。
  • 竞争的特点是主要企业实施产品发布、分销联盟和策略伙伴关係关係等策略，以大幅扩大市场占有率。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章放射性皮肤炎市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 放射性皮肤炎市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章放射性皮肤炎市场：依产品估计和趋势分析

  • 全球放射性皮肤炎市场：产品仪表板
  • 全球放射性皮肤炎市场：产品变化分析
  • 2018-2030年全球放射性皮肤炎市场规模、预测与趋势分析
  • 局部的
    • 皮质类固醇
    • 亲水霜
    • 抗生素
    • 其他的
  • 敷料
    • 水凝胶和亲水胶体敷料
    • 无防刺膜
    • 用蜂蜜浸湿的纱布
    • 硅胶涂层敷料
    • 其他的

第五章放射性皮肤炎市场：依通路估算与趋势分析

  • 全球放射性皮肤炎市场：分销通路仪表板
  • 全球放射性皮肤炎市场：分销通路波动分析
  • 2018-2030年全球放射性皮肤炎市场规模、预测与趋势分析
  • 医院药房
  • 零售药房
  • 网路药房

第六章放射性皮肤炎市场：按国家、产品和分销管道分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 主要製造商的最新趋势和影响分析
  • 公司/竞争对手分类
  • 2024年主要企业市场占有率分析
  • 公司简介
    • Stratpharma AG
    • Smith &Nephew
    • Molnlycke Health Care AB
    • Derma Sciences Inc.
    • ConvaTec Inc.
    • BMG Pharma SRL
    • Acelity
    • 3M
    • Alliqua BioMedical
Product Code: GVR-1-68038-857-2

Radiodermatitis Market Growth & Trends:

The global radiodermatitis market size is expected to reach USD 557.1 million by 2030, and market is projected to grow at a CAGR of 4.0% from 2025 to 2030, according to a new report by Grand View Research, Inc.. The rising global incidence of cancer is a key factor driving the market growth. As cancer rates increase, more patients are receiving radiation therapy as part of their treatment plans. In February 2024, the WHO reported that around 20% of individuals are expected to be diagnosed with cancer at some point in their lives, with roughly 1 in 9 men and 1 in 12 women succumbing to the illness, resulting in a growing need for effective solutions to manage side effects like radiodermatitis. This condition, marked by skin irritation and damage from radiation exposure, calls for specialized treatments focused on alleviating symptoms and promoting healing. Consequently, pharmaceutical and medical device companies prioritize developing innovative therapies and products to address the radiodermatitis industry.

The growing awareness and emphasis on patient care during cancer treatment play a significant role in improving outcomes. Healthcare providers are increasingly acknowledging the need to address side effects related to radiation therapy, such as radiodermatitis. The May 2024 review in Bioengineering & Translational Medicine highlighted the clinical use of hydrogels since the late 1980s across drug delivery, cosmetics, and tissue regeneration. Recent advancements in polymer chemistry and fabrication have resulted in over 100 FDA and EMA-approved hydrogel products derived from natural, synthetic, or combined materials. These products serve various purposes, including tissue regeneration, facial correction, wound dressing, and drug delivery, and include both injectable and non-injectable options in clinical trials.

Radiodermatitis Market Report Highlights:

  • The topical products segment dominated in 2024 with a market share of 71.7%, primarily due to their easy accessibility, enhanced convenience, and advantages over oral alternatives. These products are expected to experience significant growth thanks to their diverse formulations, including creams, gels, and ointments tailored to meet patient needs.
  • In terms of distribution channel, the retail pharmacies segment accounted for a substantial share of 39.4% in 2024 owing to the rising number of pharmacies. Retail pharmacies capture a large percentage of prescriptions written in the hospital.
  • Europe dominated the market globally with a market share of 34.0% due to advanced healthcare infrastructure, high awareness of skin care treatments, and a large patient population undergoing radiation therapy.
  • North America accounted for the second-largest market share due to significant R&D initiatives that have created promising growth opportunities. Advanced therapeutic products in the region are a key factor contributing to its growth in the radiodermatitis industry.
  • The competition features key players implementing strategies like product launches, distribution agreements, and strategic partnerships, which have greatly expanded their market share.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Distribution Channel
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Distribution Channel outlook
  • 2.3. Competitive Insights

Chapter 3. Radiodermatitis Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of cancer
      • 3.2.1.2. Advancements in dermatological treatments
      • 3.2.1.3. Growing awareness
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High treatment costs
      • 3.2.2.2. Limited availability of specialized products
  • 3.3. Radiodermatitis Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Radiodermatitis Market: Product Estimates & Trend Analysis

  • 4.1. Global Radiodermatitis Market: Product Dashboard
  • 4.2. Global Radiodermatitis Market: Product Movement Analysis
  • 4.3. Global Radiodermatitis Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 4.4. Topical
    • 4.4.1. Topical market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Corticosteroids
      • 4.4.2.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Hydrophilic Creams
      • 4.4.3.1. Hydrophilic creams market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4. Antibiotics
      • 4.4.4.1. Antibiotics market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5. Others
      • 4.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Dressings
    • 4.5.1. Dressings market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.2. Hydrogel & Hydrocolloid Dressing
      • 4.5.2.1. Hydrogel & hydrocolloid dressing market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.3. No Sting Barrier Films
      • 4.5.3.1. No sting barrier films market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.4. Honey Impregnated Gauze
      • 4.5.4.1. Honey impregnated gauze market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.5. Silicone Coated Dressings
      • 4.5.5.1. Silicone coated dressings market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.6. Others
      • 4.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Radiodermatitis Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Global Radiodermatitis Market: Distribution Channel Dashboard
  • 5.2. Global Radiodermatitis Market: Distribution Channel Movement Analysis
  • 5.3. Global Radiodermatitis Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 5.4. Hospital pharmacies
    • 5.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. Retail pharmacies
    • 5.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Online pharmacies
    • 5.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Radiodermatitis Market: Regional Estimates & Trend Analysis by Country, Product and Distribution Channel

  • 6.1. Regional Dashboard
  • 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Stratpharma AG
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Smith & Nephew
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Molnlycke Health Care AB
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Derma Sciences Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. ConvaTec Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. BMG Pharma S.R.L.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Acelity
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. 3M
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Alliqua BioMedical
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 5 U.S. radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 Canada radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 8 Canada radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Mexico radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 10 Mexico radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Europe radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 13 Europe radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Germany radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 15 Germany radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 UK radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 17 UK radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 18 France radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 19 France radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Italy radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 21 Italy radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 Spain radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 23 Spain radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Denmark radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 25 Denmark radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Sweden radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 27 Sweden radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Norway radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 29 Norway radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 31 Aisa Pacific radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 China radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 34 China radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 35 Japan radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 36 Japan radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 India radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 38 India radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 South Korea radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 40 South Korea radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Australia radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 42 Australia radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Thailand radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 44 Thailand radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Latin America radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 46 Latin America radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 47 Latin America radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Brazil radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 49 Brazil radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Argentina radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 51 Argentina radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 MEA radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 54 MEA radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 South Africa radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 56 South Africa radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 UAE radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 60 UAE radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Kuwait radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 62 Kuwait radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Radiodermatitis market: market outlook
  • Fig. 14 Radiodermatitis competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Radiodermatitis market driver impact
  • Fig. 18 Radiodermatitis market restraint impact
  • Fig. 19 Radiodermatitis market: Type movement analysis
  • Fig. 20 Radiodermatitis market: Type outlook and key takeaways
  • Fig. 21 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Hydrophilic creams market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Dressings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Hydrogel & hydrocolloid dressings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 No sting barrier films market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Honey impregnated gauze market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Silicone coated dressings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Radiodermatitis market: Distribution channel movement analysis
  • Fig. 33 Radiodermatitis market: Distribution channel outlook and key takeaways
  • Fig. 34 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 North America, by country
  • Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. key country dynamics
  • Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada key country dynamics
  • Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Mexico key country dynamics
  • Fig. 44 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 UK key country dynamics
  • Fig. 47 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Germany key country dynamics
  • Fig. 49 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 France key country dynamics
  • Fig. 51 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Italy key country dynamics
  • Fig. 53 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Spain key country dynamics
  • Fig. 55 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark key country dynamics
  • Fig. 57 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Sweden key country dynamics
  • Fig. 59 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Norway key country dynamics
  • Fig. 61 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 China key country dynamics
  • Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Japan key country dynamics
  • Fig. 66 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 India key country dynamics
  • Fig. 68 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Thailand key country dynamics
  • Fig. 70 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 South Korea key country dynamics
  • Fig. 72 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Australia key country dynamics
  • Fig. 74 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Brazil key country dynamics
  • Fig. 77 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Argentina key country dynamics
  • Fig. 79 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 South Africa key country dynamics
  • Fig. 82 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Saudi Arabia key country dynamics
  • Fig. 84 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 UAE key country dynamics
  • Fig. 86 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Kuwait key country dynamics
  • Fig. 88 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Market share of key market players - radiodermatitis market